Glynis Kolling, a research scientist in a quiet lab in Charlottesville, leans over a glowing screen displaying intricate maps of bacterial metabolism—digital blueprints of life too small to see but powerful enough to shape human health. She and her team at the University of Virginia School of Medicine have just uncovered a startling truth about the probiotic supplements lining the shelves of CVS, Walgreens, and Walmart: despite bold claims ranging from gut health to vaginal wellness, the 352 products they analyzed contain just 36 unique bacterial species. More than half of these supplements rely on a single strain, and even the most complex blend caps out at 17 species—mostly variations of Lactobacillus, the same microbes found in everyday yogurt. The study, published in Nature Microbiology, reveals a market flooded with repetition, not innovation.
This lack of diversity matters because the human microbiome—home to trillions of microbes—is now understood to play a vital role in everything from digestion to immune function and mental health. Yet while the FDA has approved only two microbial therapies (both for recurrent C. difficile infections), thousands of unregulated probiotic supplements flood the market, often with little scientific backing for their health claims. The UVA team, led by biomedical engineer Jason Papin, Ph.D., wanted to know whether the bacteria in these products were truly suited to their promised benefits. Their answer: there’s no consistent pattern linking specific microbial combinations to specific health outcomes. In other words, the science isn’t keeping pace with the marketing.
But the researchers aren’t just critiquing the status quo—they’re building a path forward. They’ve developed HaPaPro, a suite of over 1,000 computational models that simulate how different bacteria metabolize nutrients and interact with the human body. Using these models, they’ve already identified promising microbes that could help restore balance in the vaginal microbiome and prevent bacterial vaginosis—a condition affecting millions of women, linked to pregnancy complications and increased risk of STIs. This breakthrough shows that precision, not guesswork, could be the future of probiotics.
"It is truly fascinating to discover that these probiotic bacteria hold a unique, specialized niche among the trillions of microbes in and on the human body," Kolling says. With tools like HaPaPro, scientists can move beyond trial and error, designing targeted therapies that actually deliver on their promises. The probiotic industry may be built on shaky science today, but the foundation for something better is already taking shape in a Charlottesville lab—one digital model at a time.